News

Corplex Donepezil Skin Patch Therapy Moves to Phase 1 Trial

A once-weekly transdermal patch delivers the most commonly prescribed treatment for Alzheimer’s disease in a way that is biologically equivalent to taking the medication orally, according to preliminary pilot study results. Corium International conducted the bioequivalence (BE) pilot study on its lead product, Corplex, which delivers donepezil — the same active…

ALZ-801 Works Against Alzheimer’s by Preventing Protein Component Clumping, Study Reports

The Alzheimer’s therapy ALZ-801 works by preventing protein components from clumping together to trigger the amyloid plaque accumulation in the brain that causes the disease, researchers say. Disease-modifying drugs for Alzheimer’s and other neurodegenerative diseases could evolve from the findings, the team said. Researchers knew that tramiprosate, the active ingredient in …

Schizophrenia Treatment, Brexpiprazole, Seen to Ease Agitation in Alzheimer’s Patients in Phase 3 Trial

The schizophrenia medication Rexulti (brexpiprazole) reduced agitation in patients with Alzheimer’s disease, newly released data from two Phase 3 clinical trials of the drug show. The studies highlight that efforts are ongoing to target symptoms — other than dementia itself — to improve the quality of life of Alzheimer’s…

ProMIS Neurosciences Presents Alzheimer’s Advances, PMN 310 Updates, at 2017 AAN Meeting

Canada’s ProMIS Neurosciences today presented the latest results of its Alzheimer’s disease therapeutic program and discussed its lead candidate drug PMN 310 on the final day of the April 22-28 annual meeting of the American Academy of Neurology in Boston. The company’s chief development officer, Johanne Kaplan, presented the poster, “Achieving the optimal profile…